Today, CLSA issued a statement applauding the Congressional passage of S. 1379, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019, legislation that is key to strengthening our national preparedness and response for public health emergencies and accelerating medical countermeasure research and development. Share links below and more information attached.
New medicines, devices, and diagnostics produced by the life sciences community in California are giving clinicians better tools to fight disease and improve quality of life for patients around the world. CLSA President & CEO Mike Guerra pens an op-ed in Xconomy on the strength and growth of California’s life sciences sector.
On May 9, 2019, Governor Newsom released a revised state budget proposal (known as the “May Revise”) focusing on health care, housing, early childhood, and education. The budget addressed his priorities for the “Healthcare for All” policy agenda, which includes expanding Medi-Cal coverage to young adults regardless of their immigration status.
Two bills sponsored by the organizations Physicians Committee for Responsible Medicine and Social Compassion in Legislation were defeated by CLSA and fellow research and education-focused stakeholders in recent weeks.
On Thursday, May 16, CLSA’s advocacy paid off when CMS released its final rule and fact sheet. In the final rule, CMS decided to not adopt two proposals which would have allowed Part D plans to exclude a protected class drug from their formularies for multiple years if price-growth exceeded an inflation index as well as if the drug represented a new formulation that is not a significant innovation over the original product.
CLSA President & CEO Mike Guerra recently sat down with Global Business Reports to discuss CLSA’s mission, as well as the commitment of our members in helping patients, while boosting investment, innovation and job creation in California’s life sciences sector.
Today, CLSA announced the transitional board appointment of Melinda Richter, Global Head, Johnson & Johnson Innovation – JLABS from Vice Chair to Chair of CLSA’s Board of Directors. Alex Kelly, Executive Vice President, Corporate Affairs and Chief Communications Officer, Allergan, will move into the position of Vice Chair, ceding the role of Treasurer to Jeff Jonker, President and CEO, Ambys Medicines.
CLSA today announced the appointment of Molly Fishman as Director of Federal Government Relations based in CLSA’s Washington, D.C. Office. Fishman joins CLSA following many years on Capitol Hill, where she most recently served as Legislative Director for U.S. Representative Jackie Speier.
On April 3, 2019, CLSA cohosted a multi-state life sciences association bipartisan congressional briefing on “Life Sciences Innovation: From Research to Cures.” The event was convened in collaboration with Rep. Scott Peters (D-San Diego) and Rep. John Curtis (R-Utah).
With the help of a broad coalition reflecting every segment of our membership, CLSA was instrumental in defeating a bill, Assembly Bill 889, that would have established an on-line publicly searchable database of California researchers conducting animal research.